This webcourse was originally presented as a satellite symposium at the 2009 Radiological Society of North America Scientific Assembly and Annual Meeting on December 1, 2009 at the Palmer House Hilton Hotel in Chicago, IL.
Click here for a preview of the slide presentations. They can also be downloaded.
There have been significant improvements over the last decade in imaging technologies used for the diagnostic evaluation of aortoiliac occlusive disease (AOD), creating a performance gap among radiologists who do not take advantage of the latest technological advancements. Magnetic resonance angiography (MRA) has replaced catheter x-ray angiography for most evaluations, and despite the recent regulatory approval of gadofosveset for use with MRA of the AOD, radiologists continue to use unapproved extracellular contrast agents.
Gadofosveset-enhanced MRA increases spatial resolution, and reduces the rate of uninterpretable images, as well as reader variability, compared to unenhanced MRA. Radiologists need to understand the importance and clinical impact of this technology. Adoption and implementation of gadofosveset-enhanced MRA can substantially improve patient care and clinical outcomes.
This educational program will enhance radiologists' awareness of the latest technological advancements in the area of contrast agents for use with MRA. It will clarify issues surrounding their appropriate use, and provide radiologists with a keen understanding of the clinical applications for MRA evaluation of a variety of atherosclerotic diseases.
 |
E. Kent Yucel, MD, FACR—Chair (read bio) Chairman of Radiology, Tufts Medical Center Professor of Radiology, Tufts University School of Medicine Boston, MA |
 |
Neil M. Rofsky, MD (read bio) Professor of Radiology Harvard Medical School Director, MRI Beth Israel Deaconess Medical Center Boston, MA |
 |
Carlo Catalano, MD (read bio) Associate Professor Department of Radiological Sciences University of Rome La Sapienza Rome, Italy |
This program was developed for medical imaging professionals, including radiologists, radiologic technologists, medical physicists, allied scientists, and other diagnostic imaging professionals.
This activity was designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.
At the conclusion of this activity, participants should be able to:
This educational activity was developed in adherence with the policies and guidelines, including the Standards for Commercial Support, set forth by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of this medical education program are required to disclose any relevant financial relationships with any commercial interest. Any conflicts are identified and resolved in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. Disclosures will be made known to the participants prior to the activity.
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
E. Kent Yucel, MD, FA CR—Speaker: Lantheus Medical Imaging.
Neil M. Rofsky, MD—Advisory Board: Bayer Healthcare Pharmaceuticals; Speaker: Bayer Healthcare Pharmaceuticals; Consultant: EPIX Pharmaceuticals, Lantheus Medical Imaging.
Carlo Catalano, MD—Nothing to Disclose.
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Carole Drexel, PhD; Bradley Pine; Mira Valkova; Blair St. Amand; Dana Simpler, MD: Nothing to Disclose
The contents of some educational activities may contain discussions of non-approved or off label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
Presented by: |
This program is supported through an educational grant from |
By clicking this button, you are agreeing that you have read and understood the CE Statements above.
RSNA does not allow programs developed in conjunction with their annual meeting to provide CME/CE credit to participants.
As a result no credit is offered for the completion of this educational activity. This activity was developed as a fair-balanced
program and in accordance with ACCME guidelines.
